INCY this company has awesome drugs...Health Care Conference on Wednesday, September 9, 2009 at 10:00 a.m.

drugs for oncology, inflammation and diabetes. Incyte’s most advanced compound, INCB18424, is in Phase III development for myelofibrosis.

Three-month Phase IIb efficacy study in patients with type 2 diabetes is currently underway and involves five doeses of INCB13739 versus placebo. Results from this trial are expected in mid-2009.

2009 Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 15, 2009 at 11:30 a.m. (ET) in New York City; and
UBS 2009 Global Life Sciences Conference on Monday, September 21, 2009 at 12:00 p.m. (ET) in New York City.
Well from these conferences we expect some very important results on a few of there
billion dollar vaule.